HCPCS Index Logo

HCPCS Codes Alphabetical Index

— Q —  /  — Q2 —

Q2 — Demonstration procedure/service
Code added date: 19920101
Code effective date: 20170101
Q2 in HTML format HTML  |  Q2 in PDF (Portable Document Format) PDF  |  Q2 in plain Text format TXT
Q2004 — Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
Code added date: 20000701
Code effective date: 20240101
Q2004 in HTML format HTML  |  Q2004 in PDF (Portable Document Format) PDF  |  Q2004 in plain Text format TXT
Q2009 — Injection, fosphenytoin, 50 mg phenytoin equivalent
Code added date: 20000701
Code effective date: 20200101
Q2009 in HTML format HTML  |  Q2009 in PDF (Portable Document Format) PDF  |  Q2009 in plain Text format TXT
Q2017 — Injection, teniposide, 50 mg
Code added date: 20000701
Code effective date: 20230101
Q2017 in HTML format HTML  |  Q2017 in PDF (Portable Document Format) PDF  |  Q2017 in plain Text format TXT
Q2026 — Injection, radiesse, 0.1 ml
Code added date: 20100701
Code effective date: 20200101
Q2026 in HTML format HTML  |  Q2026 in PDF (Portable Document Format) PDF  |  Q2026 in plain Text format TXT
Q2027 — Injection, sculptra, 0.1 ml
Code added date: 20100701
Code effective date: 20140101
Q2027 in HTML format HTML  |  Q2027 in PDF (Portable Document Format) PDF  |  Q2027 in plain Text format TXT
Q2028 — Injection, sculptra, 0.5 mg
Code added date: 20140101
Code effective date: 20190101
Q2028 in HTML format HTML  |  Q2028 in PDF (Portable Document Format) PDF  |  Q2028 in plain Text format TXT
Q2033 — Influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)
Code added date: 20130701
Code effective date: 20140101
Q2033 in HTML format HTML  |  Q2033 in PDF (Portable Document Format) PDF  |  Q2033 in plain Text format TXT
Q2034 — Influenza virus vaccine, split virus, for intramuscular use (agriflu)
Code added date: 20120701
Code effective date: 20140101
Q2034 in HTML format HTML  |  Q2034 in PDF (Portable Document Format) PDF  |  Q2034 in plain Text format TXT
Q2035 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
Code added date: 20110101
Code effective date: 20140101
Q2035 in HTML format HTML  |  Q2035 in PDF (Portable Document Format) PDF  |  Q2035 in plain Text format TXT
Q2036 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
Code added date: 20110101
Code effective date: 20140101
Q2036 in HTML format HTML  |  Q2036 in PDF (Portable Document Format) PDF  |  Q2036 in plain Text format TXT
Q2037 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
Code added date: 20110101
Code effective date: 20140101
Q2037 in HTML format HTML  |  Q2037 in PDF (Portable Document Format) PDF  |  Q2037 in plain Text format TXT
Q2038 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
Code added date: 20110101
Code effective date: 20140101
Q2038 in HTML format HTML  |  Q2038 in PDF (Portable Document Format) PDF  |  Q2038 in plain Text format TXT
Q2039 — Influenza virus vaccine, not otherwise specified
Code added date: 20110101
Code effective date: 20170101
Q2039 in HTML format HTML  |  Q2039 in PDF (Portable Document Format) PDF  |  Q2039 in plain Text format TXT
Q2040 — Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Code added date: 20180101
Code effective date: 20190101
Q2040 in HTML format HTML  |  Q2040 in PDF (Portable Document Format) PDF  |  Q2040 in plain Text format TXT
Q2041 — Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20180401
Code effective date: 20190101
Q2041 in HTML format HTML  |  Q2041 in PDF (Portable Document Format) PDF  |  Q2041 in plain Text format TXT
Q2042 — Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20190101
Code effective date: 20190101
Q2042 in HTML format HTML  |  Q2042 in PDF (Portable Document Format) PDF  |  Q2042 in plain Text format TXT
Q2043 — Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
Code added date: 20110701
Code effective date: 20110701
Q2043 in HTML format HTML  |  Q2043 in PDF (Portable Document Format) PDF  |  Q2043 in plain Text format TXT
Q2045 — Injection, human fibrinogen concentrate, 1 mg
Code added date: 20120701
Code effective date: 20130101
Q2045 in HTML format HTML  |  Q2045 in PDF (Portable Document Format) PDF  |  Q2045 in plain Text format TXT
Q2046 — Injection, aflibercept, 1 mg
Code added date: 20120701
Code effective date: 20130101
Q2046 in HTML format HTML  |  Q2046 in PDF (Portable Document Format) PDF  |  Q2046 in plain Text format TXT
Q2047 — Injection, peginesatide, 0.1 mg (for esrd on dialysis)
Code added date: 20120701
Code effective date: 20130101
Q2047 in HTML format HTML  |  Q2047 in PDF (Portable Document Format) PDF  |  Q2047 in plain Text format TXT
Q2048 — Injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg
Code added date: 20120701
Code effective date: 20130101
Q2048 in HTML format HTML  |  Q2048 in PDF (Portable Document Format) PDF  |  Q2048 in plain Text format TXT
Q2049 — Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Code added date: 20120701
Code effective date: 20120701
Q2049 in HTML format HTML  |  Q2049 in PDF (Portable Document Format) PDF  |  Q2049 in plain Text format TXT
Q2050 — Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Code added date: 20130701
Code effective date: 20130701
Q2050 in HTML format HTML  |  Q2050 in PDF (Portable Document Format) PDF  |  Q2050 in plain Text format TXT
Q2051 — Injection, zoledronic acid, not otherwise specified, 1mg
Code added date: 20130701
Code effective date: 20140101
Q2051 in HTML format HTML  |  Q2051 in PDF (Portable Document Format) PDF  |  Q2051 in plain Text format TXT
Q2052 — Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
Code added date: 20140401
Code effective date: 20230701
Q2052 in HTML format HTML  |  Q2052 in PDF (Portable Document Format) PDF  |  Q2052 in plain Text format TXT
Q2053 — Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20210401
Code effective date: 20210401
Q2053 in HTML format HTML  |  Q2053 in PDF (Portable Document Format) PDF  |  Q2053 in plain Text format TXT
Q2054 — Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20211001
Code effective date: 20211001
Q2054 in HTML format HTML  |  Q2054 in PDF (Portable Document Format) PDF  |  Q2054 in plain Text format TXT
Q2055 — Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20220101
Code effective date: 20240404
Q2055 in HTML format HTML  |  Q2055 in PDF (Portable Document Format) PDF  |  Q2055 in plain Text format TXT
Q2056 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20221001
Code effective date: 20221001
Q2056 in HTML format HTML  |  Q2056 in PDF (Portable Document Format) PDF  |  Q2056 in plain Text format TXT
Q2057 — Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20250401
Code effective date: 20250401
Q2057 in HTML format HTML  |  Q2057 in PDF (Portable Document Format) PDF  |  Q2057 in plain Text format TXT
Q2058 — Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Code added date: 20250701
Code effective date: 20250701
Q2058 in HTML format HTML  |  Q2058 in PDF (Portable Document Format) PDF  |  Q2058 in plain Text format TXT